Worry-free AAV gene therapy manufacturing, right this way.

At Viralgen, we’re all-in on AAV. It’s made us a leader in rAAV-based gene therapy manufacturing, with unmatched expertise and the largest manufacturing capacity dedicated to AAV.

Find out how you can take advantage of our Aava™ manufacturing platform—the high-performance, real-world-ready solution that can get high-potential gene therapies to market quickly and efficiently at impressive scale, with better predictability and deeper data.

30+

AAV serotypes

100%

success rate for
IND/IMPD dossiers

2,000+

AAV batches

Schedule A Meeting

Now that you know a little about us, let’s meet and talk about you.

Say hello to

Aava wordmark white

 

The first choice in AAV gene therapy manufacturing now has a first name. Learn more about the most proven platform in the industry, available only from Viralgen.

Fresh research on AAV manufacturing

Stop by Poster Hall 12 throughout the week for a quintet of research updates from the scientific and technology leads at Viralgen who are helping shape the future of AAV-based gene therapy manufacturing.

Streamlining Advanced Therapy Medicinal Product Manufacturing: A Platform Approach for Accelerating Gene Therapy Commercialization at Viralgen
Presented by Cesar Trigueros
May 15, 5:30-7pm CT
Poster Hall I2
Poster # AMA988


Benefits of High-Throughput Sequencing-Based Methods for In-Depth Characterization of Recombinant AAV Products
Presented by Sonia Stinus
May 14, 5:30-7pm CT
Poster Hall I2
Poster # AMA905


Enhancing the Upstream Performance of Adeno-Associated Virus (AAV) Vector Manufacturing via Multivariate Data Analysis
Presented by Ainara Apezteguia
May 15, 5:30-7pm CT
Poster Hall I2
Poster # AMA1624


Leveraging Historical Data and Percentile based Modeling for Improved AAV Production Scaling
Presented by Itsasne Arangoa
May 15, 5:30-7pm CT
Poster Hall I2
Poster # AMA1546


Integrating Raman Spectroscopy and Genome-Scale Modeling to Enhance AAV Upstream Manufacturing
Presented by Itsasne Arangoa
May 13, 6-7:30pm CT
Poster Hall I2
Poster # AMA1539


Let’s Connect

Bayer fully supports coordinated vulnerability disclosure and encourages security researchers who choose to engage in these actions to do so in a responsible manner.

Coordinated Vulnerability Disclosure Statement